Fillers
POEM
Exemestane is better than tamoxifen in years 2-5 after breast cancer
BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7457.0-f (Published 08 July 2004) Cite this as: BMJ 2004;329:0-fQuestion Does exemestane improve outcomes in patients with breast cancer when treatment with it starts 2-3 years after diagnosis?
Synopsis Tamoxifen is the current standard of care for the treatment of oestrogen receptor positive breast cancer in postmenopausal women. Exemestane is an aromatase inhibitor (they block the conversion of androgens to oestrogen) and may be superior to tamoxifen in patients with metastatic disease. After 2-3 years of tamoxifen therapy, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.